| Field | Specification |
|---|---|
| Alternative names | Mycophenolate sodium |
| CAS no. | |
| Applications | |
| Source | Endogenous metabolite |
| Molecular weight | |
| Molecular formula | C17H19NaO6 |
| Purity | |
| Activity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Mycophenolic acid sodium, also known as Mycophenolate sodium, is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) with an EC50 of 0.24 μM. It shows antiviral activity against a wide range of RNA viruses, including influenza, and acts as an immunosuppressive agent. It also has antiangiogenic and antitumor effects[1][2]. It is supplied as a white to off-white solid (C17H19NaO6, MW 342.32) at 99.98% purity.
Physical & Chemical Properties
| CAS Number | 37415-62-6 |
|---|---|
| Molecular Formula | C17H19NaO6 |
| Molecular Weight | 342.32 g/mol |
| Purity | 99.98% |
| Appearance | Solid |
| Color | White to off-white |
| Structure Classification | Phenols Monophenols Ketones, Aldehydes, Acids |
| SMILES | O=C(O[Na])CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC |
| Signaling Pathway | Apoptosis; Anti-infection; Metabolic Enzyme/Protease |
| Bioactivity Class | Human Endogenous Metabolite |
| Initial Source | Endogenous metabolite |
| Solubility | In Vitro: DMSO: 175 mg/mL (511.22 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: 100 mg/mL (292.12 mM; Requires sonication) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 175 mg/mL (511.22 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | 100 mg/mL (292.12 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
Data provided by the manufacturer.
In Vitro
Mycophenolic acid sodium shows antiviral effects against a broad range of RNA viruses, such as influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus[1]. The rate-limiting enzyme of de novo guanosine nucleotide synthesis is IMPDH[2]. Mycophenolic acid sodium (0.01-1 μM; 72 hours) displays preferential antiproliferative activity toward endothelial cells and fibroblasts. For antimitotic effects, endothelial cells prove the most sensitive to Mycophenolic acid treatment, with an IC50 <500 nM[2]. Fibroblasts also tend to undergo Mycophenolic acid-induced cell cycle inhibition, though with a higher IC50 (<1 μM) than seen in endothelial cells. Intermediate sensitivity, with an IC50 >1 μM, is shown by two human tumor lines: A549 (non-small cell lung cancer) and PC3 (prostate cancer). U87 glioblastoma cells prove resistant to Mycophenolic acid sodium treatment up to 1 μM[2]. Mycophenolic acid sodium (0.05-2 μM; 18 hours) down-regulates HDAC2 and MYC in a dose-dependent manner and up-regulates NDRG1[2].
Cell Proliferation Assay[2]
| Cell Line | Primary isolated human dermal microvascular endothelial cells (HDMVEC), fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells. |
|---|---|
| Concentration | 0.01, 0.1, 1 μM |
| Incubation Time | 72 hours |
| Result | Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity. |
Western Blot Analysis[2]
| Cell Line | HDMVEC |
|---|---|
| Concentration | 0, 0.05, 0.1, 0.5, 1, and 2 μM |
| Incubation Time | 18 hours |
| Result | Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1. |
In Vivo
Mycophenolic acid sodium (120 mg/kg; oral gavage; b.i.d.) exerts antitumor effects by modulating the tumor microenvironment, and markedly inhibits U87 tumor growth in vivo in BALB/c nude mice[2].
| Animal Model | Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model[2] |
|---|---|
| Dosage | 120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) |
| Administration | Oral gavage; b.i.d. |
| Result | MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice. Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. Nat Immunol 2024 Apr;25(4):659-670. PMID: 38499799
Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. Nat Commun 2024 Nov 12;15(1):9515. PMID: 39532854
12R-HETE acts as an endogenous ligand for Nur77 in the intestines and regulates NKp46+ ILC3 development. Sci Adv 2026 Feb 20;12(8):eadz8405. PMID: 41719391
Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer. J Transl Med 2024 Feb 3;22(1):133. PMID: 38310229
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Sci Signal 2024 Nov 26;17(864):eadp1375. PMID: 39591412
Mechanism of Intestinal Epithelial Absorption and Electrophysiological Regulation of the Shrimp Peptide QMDDQ. J Agric Food Chem 2024 Jan 10;72(1):326-338. PMID: 38155399
Simultaneous Quantification of Mycophenolic Acid and Its Glucuronide Metabolite in PBMCs from Kidney Transplant Recipients by LC-MS/MS. Drug Des Devel Ther 2026 Jul 23:20:622839. PMID: 42517052
Infectious cDNA Clone of Chikungunya Virus 181/25 for Antiviral Assay Development. ACS Omega 2025 Dec 8;10(50):62145-62156. PMID: 41476561
MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies. Virol Sin 2026 Jul 23:S1995-820X(26)00122-7. PMID: 42492700
The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells. BMC Cancer 2025 Sep 30;25(1):1463. PMID: 41029501
